5-bromo-2-methyl-benzo[de]isoquinoline-1,3-dione | 32330-57-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 5-bromo-2-methyl-benzo[de]isoquinoline-1,3-dione
• 英文别名: 3-Brom-N-methylnaphthalimid；5-bromo-2-methyl-1H-benzo[de]isoquinoline-1,3(2H)-dione；5-bromo-2-methylbenzo[de]isoquinoline-1,3-dione
• CAS: 32330-57-7
• 化学式: C₁₃H₈BrNO₂
• 分子量: 290.116
• InChiKey: VSSLNSPIYFHDSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  杂氮环丁烷 、 5-bromo-2-methyl-benzo[de]isoquinoline-1,3-dione 在 二氯双[二叔丁基-(4-二甲基氨基苯基)膦]钯(II) 、 potassium tert-butylate 作用下， 以 甲苯 为溶剂， 以35%的产率得到
  参考文献：
  名称：

  通过氢键敏感荧光探针的缓冲策略对脂滴动力学进行稳定的超分辨率成像

  摘要：

  我们报告了一种探针LD-FG，用于通过使用结构照明显微镜对脂滴 (LD) 动力学进行成像。由于氢键敏感的荧光反应，LD-FG允许对 LD 进行免洗成像。用来自 LD 外部的新鲜探针分子替换光漂白的LD-FG，确保了成像的长期稳定性。使用这种缓冲荧光探针，可以可视化快速且不可预测的 LD 动态过程。

  DOI：

  10.1002/anie.202111052
• 作为产物：
  描述：

  1,8-萘二甲酸酐 在 N-溴代丁二酰亚胺(NBS) 、 硫酸 作用下， 以 四氢呋喃 为溶剂， 反应 32.0h， 生成 5-bromo-2-methyl-benzo[de]isoquinoline-1,3-dione
  参考文献：
  名称：

  MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS

  摘要：

  Compounds that have antiallergic and/or anti-inflammatory properties and methods of making thereof are disclosed. These compounds can block MMRGPRX2 and prevent or reduce mast cells activation. Pharmaceutical formulations in a unit dosage form suitable for the delivery of the compounds to a subject in need thereof are disclosed. The pharmaceutical formulations may include one or more active agents in addition to the compounds, such as one or more additional antiallergic and/or anti-inflammatory agents. The pharmaceutical formulation can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. Methods for preventing or treating pseudo allergic reactions, pseudo allergic diseases, and/or pseudo inflammatory diseases, or treating or ameliorating one or more symptoms associated with a pseudo allergic reaction, a pseudo allergic disease, and/or a pseudo inflammatory disease in a subject are also disclosed.

  公开号：

  US20220401435A1

文献信息

• 一类高亮度、高光稳定性脂滴荧光探针及其合成方法与应用
  申请人：中国科学院大连化学物理研究所

  公开号：CN112939863A

  公开（公告）日：2021-06-11

  本发明开发出了一类高亮度、高光稳定性脂滴探针及其合成方法与应用，结构特点是在萘酰亚胺母体的3‑位引入不同含氮取代基。该类探针合成方法简单，原料价廉易得。探针在质子性溶剂如水中荧光量子产率小于0.01，而在非质子性溶剂如二氯甲烷中荧光量子产率可达到0.7。这类探针有优异的亮度和光稳定性，能够快速透过细胞并富集于脂滴中，实现脂滴的免洗荧光成像，在细胞生物学研究中具有广阔的应用前景。
• Stable Super‐Resolution Imaging of Lipid Droplet Dynamics through a Buffer Strategy with a Hydrogen‐Bond Sensitive Fluorogenic Probe
  作者：Jie Chen、Chao Wang、Wenjuan Liu、Qinglong Qiao、Huan Qi、Wei Zhou、Ning Xu、Jin Li、Hailong Piao、Davin Tan、Xiaogang Liu、Zhaochao Xu

  DOI：10.1002/anie.202111052

  日期：2021.11.15

  We report a probe, LD-FG, for imaging lipid droplet (LD) dynamics by using structure illumination microscopy. LD-FG allows wash-free imaging of LDs, owing to a hydrogen-bond sensitive fluorogenic response. The replacement of photobleached LD-FG with fresh probe molecules from outside the LDs ensures the long-term stability of the imaging. With this buffering fluorogenic probe, fast and unpredictable

  我们报告了一种探针LD-FG，用于通过使用结构照明显微镜对脂滴 (LD) 动力学进行成像。由于氢键敏感的荧光反应，LD-FG允许对 LD 进行免洗成像。用来自 LD 外部的新鲜探针分子替换光漂白的LD-FG，确保了成像的长期稳定性。使用这种缓冲荧光探针，可以可视化快速且不可预测的 LD 动态过程。
• MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS
  申请人：The University of Hong Kong

  公开号：US20220401435A1

  公开（公告）日：2022-12-22

  Compounds that have antiallergic and/or anti-inflammatory properties and methods of making thereof are disclosed. These compounds can block MMRGPRX2 and prevent or reduce mast cells activation. Pharmaceutical formulations in a unit dosage form suitable for the delivery of the compounds to a subject in need thereof are disclosed. The pharmaceutical formulations may include one or more active agents in addition to the compounds, such as one or more additional antiallergic and/or anti-inflammatory agents. The pharmaceutical formulation can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. Methods for preventing or treating pseudo allergic reactions, pseudo allergic diseases, and/or pseudo inflammatory diseases, or treating or ameliorating one or more symptoms associated with a pseudo allergic reaction, a pseudo allergic disease, and/or a pseudo inflammatory disease in a subject are also disclosed.